409 related articles for article (PubMed ID: 31195849)
21. Select β-Lactam Combinations Exhibit Synergy against
Story-Roller E; Maggioncalda EC; Lamichhane G
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745389
[No Abstract] [Full Text] [Related]
22. Clomiphene Citrate Shows Effective and Sustained Antimicrobial Activity against
Lee DG; Hwang YH; Park EJ; Kim JH; Ryoo SW
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681686
[No Abstract] [Full Text] [Related]
23. Repurposing disulfiram to target infections caused by non-tuberculous mycobacteria.
Das S; Garg T; Chopra S; Dasgupta A
J Antimicrob Chemother; 2019 May; 74(5):1317-1322. PubMed ID: 30753528
[TBL] [Abstract][Full Text] [Related]
24. Epetraborole Is Active against Mycobacterium abscessus.
Ganapathy US; Gengenbacher M; Dick T
Antimicrob Agents Chemother; 2021 Sep; 65(10):e0115621. PubMed ID: 34280020
[TBL] [Abstract][Full Text] [Related]
25. The treatment of rapidly growing mycobacterial infections.
Kasperbauer SH; De Groote MA
Clin Chest Med; 2015 Mar; 36(1):67-78. PubMed ID: 25676520
[TBL] [Abstract][Full Text] [Related]
26. Managing antibiotic resistance in nontuberculous mycobacterial pulmonary disease: challenges and new approaches.
Kwon YS; Daley CL; Koh WJ
Expert Rev Respir Med; 2019 Sep; 13(9):851-861. PubMed ID: 31256694
[No Abstract] [Full Text] [Related]
27. The Role of Antibiotic-Target-Modifying and Antibiotic-Modifying Enzymes in
Luthra S; Rominski A; Sander P
Front Microbiol; 2018; 9():2179. PubMed ID: 30258428
[TBL] [Abstract][Full Text] [Related]
28. Preclinical murine models to study lung infection with Mycobacterium abscessus complex.
Nicola F; Cirillo DM; Lorè NI
Tuberculosis (Edinb); 2023 Jan; 138():102301. PubMed ID: 36603391
[TBL] [Abstract][Full Text] [Related]
29. Treatment outcomes of macrolide-susceptible Mycobacterium abscessus lung disease.
Choi H; Jhun BW; Kim SY; Kim DH; Lee H; Jeon K; Kwon OJ; Huh HJ; Ki CS; Lee NY; Shin SJ; Daley CL; Koh WJ
Diagn Microbiol Infect Dis; 2018 Apr; 90(4):293-295. PubMed ID: 29329759
[TBL] [Abstract][Full Text] [Related]
30. CRISPR Interference-Based Inhibition of MAB_0055c Expression Alters Drug Sensitivity in Mycobacterium abscessus.
Nguyen TQ; Heo BE; Park Y; Jeon S; Choudhary A; Moon C; Jang J
Microbiol Spectr; 2023 Jun; 11(3):e0063123. PubMed ID: 37158736
[TBL] [Abstract][Full Text] [Related]
31. Alternative and Experimental Therapies of
Meir M; Barkan D
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32948001
[No Abstract] [Full Text] [Related]
32. New therapeutic strategies for
Alcaraz M; Edwards TE; Kremer L
Expert Rev Anti Infect Ther; 2023; 21(8):813-829. PubMed ID: 37314394
[TBL] [Abstract][Full Text] [Related]
33. Treatment Approaches to Mycobacterium abscessus Pulmonary Disease.
Holt MR; Baird T
Clin Chest Med; 2023 Dec; 44(4):785-798. PubMed ID: 37890916
[TBL] [Abstract][Full Text] [Related]
34. Successful antibiotic treatment of pulmonary disease caused by Mycobacterium abscessus subsp. abscessus with C-to-T mutation at position 19 in erm(41) gene: case report.
Kim SY; Shin SJ; Jeong BH; Koh WJ
BMC Infect Dis; 2016 May; 16():207. PubMed ID: 27188784
[TBL] [Abstract][Full Text] [Related]
35. Advances in the management of pulmonary disease due to Mycobacterium abscessus complex.
Koh WJ; Stout JE; Yew WW
Int J Tuberc Lung Dis; 2014 Oct; 18(10):1141-8. PubMed ID: 25216826
[TBL] [Abstract][Full Text] [Related]
36. Synergistic Efficacy of β-Lactam Combinations against
Story-Roller E; Maggioncalda EC; Lamichhane G
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31109979
[No Abstract] [Full Text] [Related]
37. Mycobacterial Characteristics and Treatment Outcomes in Mycobacterium abscessus Lung Disease.
Koh WJ; Jeong BH; Kim SY; Jeon K; Park KU; Jhun BW; Lee H; Park HY; Kim DH; Huh HJ; Ki CS; Lee NY; Kim HK; Choi YS; Kim J; Lee SH; Kim CK; Shin SJ; Daley CL; Kim H; Kwon OJ
Clin Infect Dis; 2017 Feb; 64(3):309-316. PubMed ID: 28011608
[TBL] [Abstract][Full Text] [Related]
38. Treatment for Mycobacterium abscessus complex-lung disease.
Weng YW; Huang CK; Sy CL; Wu KS; Tsai HC; Lee SS
J Formos Med Assoc; 2020 Jun; 119 Suppl 1():S58-S66. PubMed ID: 32527504
[TBL] [Abstract][Full Text] [Related]
39. Anti-Mycobacterium abscessus Activity of Tuberculosis F-ATP Synthase Inhibitor GaMF1.
Ragunathan P; Dick T; Grüber G
Antimicrob Agents Chemother; 2022 May; 66(5):e0001822. PubMed ID: 35481752
[TBL] [Abstract][Full Text] [Related]
40. In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria.
Dickinson JM; Mitchison DA
Tubercle; 1987 Sep; 68(3):177-82. PubMed ID: 2834842
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
